Mocetinostat

Mocetinostat
Names
	Preferred IUPAC name N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
Identifiers
CAS Number	726169-73-9 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:197437;
ChEMBL	ChEMBL272980 ;
ChemSpider	8041206 ;
IUPHAR/BPS	7008;
KEGG	D09641;
PubChem CID	9865515;
UNII	A6GWB8T96J ;
CompTox Dashboard (EPA)	DTXSID80222945 ;
	InChI InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) Key: HRNLUBSXIHFDHP-UHFFFAOYSA-N ; InChI=1/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) Key: HRNLUBSXIHFDHP-UHFFFAOYAW;
	SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4;
Properties
Chemical formula	C23H20N6O
Molar mass	396.454 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.^[1]^[2]^[3]

Quick Facts Names, Identifiers ...

One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.^[4]

In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.^[5]

MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.^[6]

Mechanism of action